Actively Recruiting
Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry
Led by University Hospital, Grenoble · Updated on 2022-05-19
1600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Hospital, Grenoble
Lead Sponsor
C
Clinique Belledonne
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the long-term prognostic value of macrovascular and microvascular coronary artery stenoses in different types of cardiomyopathies, including ischemic, hypertrophic, dilated, and restrictive forms. The study aims to understand how bystander coronary artery disease and coronary microvascular disease affect outcomes in patients with these heart conditions. This observational research is conducted across five centers in France to provide insight into the impact of these diseases on cardiovascular prognosis. Participants with various cardiomyopathies will undergo coronary angiography, cardiac magnetic resonance imaging (CMR), tomographic coronary artery angiography, single-photon emission computed tomography (SPECT), and rest and stress trans-thoracic echocardiography (TTE). Macrovascular coronary artery disease is defined by specific stenosis levels and ischemia confirmation, while microvascular disease is identified using indices like the index of microvascular resistance (IMR) and myocardial perfusion heterogeneity imaging (MPHI). The study records these imaging results to evaluate their prognostic significance. During the study, major adverse cardiovascular events (MACE) will be assessed at 1 year, 2 years, and 5 years after enrollment. Participants are monitored through detailed cardiovascular imaging and clinical evaluations to track their health outcomes over time. This long-term follow-up will help researchers understand the relationship between coronary artery conditions and cardiomyopathy progression, contributing valuable information for patient care and management.
CONDITIONS
Brief Title
Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of ischemic cardiomyopathy
- Diagnosis of dilated cardiomyopathy
- Diagnosis of hypertrophic cardiomyopathy
- Diagnosis of restrictive cardiomyopathy
- Age between 18 and 100 years
You will not qualify if you...
- Pregnant women
- Breastfeeding women
- Patients under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 month
Participants undergo coronary angiography, cardiac magnetic resonance, tomographic coronary artery angiography, single-photon emission computed tomography, and rest and stress trans-thoracic echocardiography to assess coronary artery and microvascular disease.
1 to 2 visits depending on imaging procedures
Duration - 5 years
Participants are followed for up to 5 years to assess major adverse cardiovascular events and prognosis related to coronary artery and microvascular disease.
Visits at 1 year, 2 years, and 5 years post-enrollment
Trial Site Locations
Total: 1 location
1
University Hospital Grenoble
La Tronche, France, 38700
Actively Recruiting
Research Team
C
Clémence CHARLON
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here